Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 27, Issue 6, Pages 1102-1105Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1440-1746.2011.07036.x
Keywords
liver failure; liver transplantation; lumiracoxib
Categories
Ask authors/readers for more resources
Backgound and Aim: Significant elevations in liver transaminases were noted in some patients during pre-marketing clinical trials with lumiracoxib, a selective COX-2 inhibitor. It was withdrawn from the Australian market in August 2007, because of an association with severe liver injury. We describe in detail three cases of severe liver injury in patients taking lumiracoxib Methods: Three patients admitted to our hospital with severe liver injury and taking lumiracoxib are described in detail, together with information on a further six cases reported to the Australian Therapeutics Goods Administration (TGA), none of whom had pre-existing liver disease or obvious risk factors for liver disease. Results: Liver histology showed severe hepatic necrosis. One patient required liver transplantation and another died. Autoantibodies were detected in all three patients. As with the other six cases reported to the TGA, all were females who had been taking lumiracoxib 200400 mg daily, typically for a few months, for osteoarthritis. Conclusions: Lumiracoxib can be associated with severe liver injury. The presence of a variety of positive auto-antibodies suggests an altered immune response may be contributory.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available